KR940701397A - 불안해소 효과를 갖는 피페리딘 유도체 - Google Patents

불안해소 효과를 갖는 피페리딘 유도체

Info

Publication number
KR940701397A
KR940701397A KR1019930703860A KR930703860A KR940701397A KR 940701397 A KR940701397 A KR 940701397A KR 1019930703860 A KR1019930703860 A KR 1019930703860A KR 930703860 A KR930703860 A KR 930703860A KR 940701397 A KR940701397 A KR 940701397A
Authority
KR
South Korea
Prior art keywords
piperidine
sup
spiro
butyl
compound
Prior art date
Application number
KR1019930703860A
Other languages
English (en)
Other versions
KR100212231B1 (ko
Inventor
케이. 몰첸 에이너
크리스티안 페레가아르트 젠스
Original Assignee
에바 스테인네스
하. 룬트베크 아크티에 셀스카브
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK113191A external-priority patent/DK113191D0/da
Priority claimed from DK112991A external-priority patent/DK112991D0/da
Priority claimed from DK15792A external-priority patent/DK15792D0/da
Application filed by 에바 스테인네스, 하. 룬트베크 아크티에 셀스카브 filed Critical 에바 스테인네스
Publication of KR940701397A publication Critical patent/KR940701397A/ko
Application granted granted Critical
Publication of KR100212231B1 publication Critical patent/KR100212231B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

하기의 일반 구조식(I)을 갖는 피페리딘 화합물들은 시그마 수용체 활성도가 강하다:
상기 식(I)에서 R1은 a) 적어도 2개의 스페이서 기(spacer group)를 통해 피페리딜 N-원자에 연결되어 있는 알킬기, 알케닐기, 시클로알킬기, 시클로알케닐기, 페닐기, 시클로알킬알킬기, 시클로알케닐알킬기, 페닐알킬 또는 디페닐알킬기로 이루어지는 기 이 든지 혹은;
상기 식(I)에서, X는 CH10, O, S, SO, SO2또는 NR10이다.
한편, 상기 식(I)에서, (i) Z1과 Z2가 서로 연결되어 있을 때는 Z1이 CH2, O 또는 S이고; Z2및 Z3는 독립적으로 (CH2)n(여기서, n는 0 또는 1), 또는 S이든지, 혹은 Z1과 Z2는 둘다 -CH=CH-기를 의미할 수도 있든지; 또는 Z3가 (CH2)n(여기서, n=0)일 때에, Z1과 Z2는 둘다 3개의 2가기(二價基)를 의미할 수도 있고; 또는 ii) R1이 상기 b)에 정의된 기라면, Z1과 Z2는 또한 결합되어 있지 않을 수도 있는데, 이 경우에 Z1은 치환기이고, Z2는 수소이고, Z3는 (CH2)n(여기서, n=0)이다.
더욱이, 이 화합물들은 동물 모델에서, 불안 해소 효과가 있음이 나타났다. 따라서, 이 화합물들은 불안, 정신병, 간질, 운동장애, 운동신경장애, 건망증, 뇌혈관질환, 알쯔하이머타입의 노인성 치매, 또는 파킨슨병 치료용의 약품으로 유용하게 쓰인다.

Description

불안해소 효과를 갖는 피페리딘 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 불안, 정신병, 간질, 운동장애, 운동신경장애, 건망증, 뇌혈관질환, 알쯔하이머 타입의 노인성 치매, 또는 파킨슨병 치료용의 약제 제조용으로 쓰기 위한 하기의 일반 구조식 I을 갖는 피페리딘 화합물 또는 이 화합물의 산 부가염 혹은 프로-드러그의 사용.
    [상기식에서, R1은 a) -D-B-A-R기(基)이고, 여기서 B는 분기쇄 또는 직쇄로 연결되어 있을 수 있고, 선택적으로 히드록시로 치환될 수 있고, 2 내지 24개의 탄소원자를 가지는 지방족 카르복시산으로 에스테르화되어질 수도 있는 알킬렌, 알케닐렌 및 알키닐렌 중에서 선택되는 19개 까지의 스페이서그룹(spacer group)이고; A는 O, S, SO, SO2및
    (여기서, W는 0 또는 S이고 점선은 선택적 결합을 표시)로부터 선택되는 하나의 ‘결합’ 또는 2가(價)의 기이고; R은 알킬, 알케닐, 시클로알킬, 시클로알케닐, 페닐, 시클로알킬 알킬, 시클로알케닐알킬, 페닐알킬, 디페닐알킬, 한 두개 히드록시기로 대체되어 있으며 2 내지 24개의 탄소원자를 가지는 지방족 카르복시산으로 선택적으로 에스테르화 되어 있을 수도 있는 알킬기, 그리고 페닐고리에 한개 이상의 치환기가 선택적으로 치환되어 있는 페닐기; 그리고 D는 CR8R9(여기서 R8및 R9는 아래에 R4내지 R7에 대해 정의된 치환된 또는 시클로알킬렌기로부터 독립적으로 선택); b) 상기 I식에서 R1은 하기의 일반 구조식 II을 갖는 기이다:
    상기식에서, X는 CHR10, O, S, SO, SO2또는 NR10인데, 여기서 R10은 수소, 저급 알킬 또는 알케닐, 시클로알킬 또는 시클로알킬알킬, 시클로알케닐 또는 시클로알케닐알킬, 아실, 아미노알킬, 모노- 또는 디알킬아미노알킬, 술포닐 또는 아릴알킬 또는 할로겐·저급알킬·저급알콕시·히드록시·트리플루오로메틸·시아노 중에서 독립적으로 선택되는 한개 이상의 치환기로 선택적으로 치환되는 페닐이든지, 혹은 R10은 헤테로 방향족 기중에서 바람직하게는 2-티에닐, 3-티에닐, 2-푸라닐, 3-푸라닐, 2-티아조릴, 2-옥사조릴, 2-이미다조릴, 2-피리딜, 3-피리딜, 또는 4-피리딜이고; 한두개의 점선은 ‘결합’을 표시할 수도 있고; Y로 부터 나오는 점선이 ‘결합’을 의미할 때는 Y가 N 또는 CH이고; 상기의 점선이 ‘결합’을 의미하지 않을 때는 Y가 CH2, NH, C=0 또는 C=S이고; RaRbRcRd는 수소, 할로겐, 저급알킬, 저급알콕시, 히드록시, 저급알킬티오, 저급 알킬술포닐, 저급 알킬- 또는 디알킬-아미노, 시아노, 트리플루오로메틸, 또는 트리플루오로메틸티오이고; U는 CH2, O 또는 S이고; 또는 U로부터 나오는 점선들 중의 하나가 ‘결합’을 가리킬때는 U는 CH이고; U와 Q1또는 U와 Q2사이의 결합이 삼중결합일 수도 있는데, 이 경우에는 U가 “C”이고; Q1은 한 결합, 알킬렌 또는 알케닐렌으로부터 선택되고 Q2는 적어도 두 개의 C원자, 알케닐렌 또는 Q2′ D기(여기서 Q2′는 Q2에 대한 정의와 같고, D는 위에 정의되어 있다)를 갖는 알킬렌이고, Q1및 Q2는 둘다 2 내지 20개의 탄소원자를 가지고, 2 내지 24개의 탄소원자를 가지는 지방족 카르복시산으로 선택적으로 에스테르화된 한개 이상의 히드록시기로 선택적으로 치환된 것이고; R2및 R3은 독립적으로 수소, 저급알킬이든지, 또는 서로 연결되어 에틸렌 또는 프로필렌 다리를 형성할 수 있고; R4, R5, R6, R7은 독립적으로 수소, 할로겐, 저급알킬, 저급알콕시, 히드록시, 저급알킬티오, 저급알킬- 또는 디알킬아미노, 시아노, 트리플루오로메틸, 또는 트리플루오로메틸티오이고; i) Z1및 Z2가 같이 연결되어 있을 경우에, Z2는 CH2, O, 또는 S이고; Z2및 Z3은 독립적으로 (CH2)n(여기서, n은 0 또는 1), O 또는 S인데, 단 조건은 Z2가 S 또는 O일 때 Z1이 O가 아닐 수도 있고, 또한 Z2와 Z3둘다 (CH2)n(여기서, n=0)이 아닐수도 있다는 것이고; 또는 Z1및 Z2는 함께 -CH=CH-기를 나타낼 수도 있고; 또는 Z3가 (CH2)n(여기서, n=0)일때, Z1및 Z2는 선택적으로 하나의 불포화 결합을 포함하고, 또한 선택적으로 하나의 O- 또는 S-헤테로 원자를 포함하는 3개의 2가의 기를 나타낼 수도 있든지; 또는 ii) R1이 상기 b)에 정의된 바의 기이라면, Z1및 Z2는 또한 연결되어 있지 않을수 있는데, 이 경우 Z1은 R4, R5, R6, R7에 대해 정의된 바의 기이고, Z2는 수소이고, Z3은 (CH2)n(여기서, n=0)이고; Z1, Z2, Z3이 상기 i)에 정의된 바의 것이고 (여기서, Z3은 n 이 0인 (CH2)n), 또 Z1및 Z2가 모두 선택적으로 하나의 불포화 결합을 포함하는 2 또는 3개의 2가의 탄화수소 기를 나타내고, 또한 R1이 상기 a)에 정의된 바의 기이라는 조건하에서는, 상기 D-B-A-R기는 페닐, -C1-3-알킬, 저급알킬 또는 저급알케닐이 아닐수도 있다.]
  2. 제1항에 있어서, 사용된 리반식 I의 화합물이, Z1및 Z2가 함께 결합되어 있고, Z1, Z2및 Z3중 적어도 하나는 O 또는 S인 화합물인 것을 특징으로 하는 피페리딘 화합물의 이용.
  3. 제2항에 있어서, 사용된 일반식 I의 화합물이 Z3은 n이 0인 (CH2)n이고, Z2는 “O” 또는 “S”이고, Z1은 CH2이거나 Z1과 Z2는 함께 CH2-O-CH2인 화합물인 것을 특징으로 하는 피페리딘 화합물의 이용.
  4. 제2항에 있어서, 사용된 일반식 I의 화합물이 Z1은 CH2, Z2가 O이고 Z3가 CH2인 것; 또는 Z3이 O이고 Z1-Z2가 CH=CH인 것; 또는 Z1은 O, Z3가 O이고 Z2는 n이 0인 (CH2)n인 화합물인 것을 특징으로 하는 피페리딘 화합물의 이용.
  5. 제1항에 있어서, 사용된 화합물이, Z1과 Z2가 함께 결합되어 있지 않고 Z3은 n=0 (CH2)n인 화합물인 것을 특징으로 하는 피페리딘 화합물의 이용.
  6. 제1항에 있어서, 사용된 일반식 I의 화합물이 1′-(3-아다만틸옥시-1-프로필) 스피로[3H-2-벤조피란-3,4′-피페리딘]; 1′-[4-(1-벤질-3-인돌일)-1-부틸]-스피로[이소벤조푸란-1(3H), 4′-피페리딘]; 1′-(3-(3-페닐이미다졸리딘-2-온-1-일)-1-프로필)스피로[이소벤조푸란-1(3H), 4′-피페리딘]; 1′-[4-[1-(4-플루오로페닐]-3-인돌일]-1-부틸]-스피로[이소벤조푸란-1(3H), 4′피페리딘]; 1,4-디히드로-1′-[4-[1-[(4-플루오로페닐)-3-인돌일]-1-부틸] 스피로[3H-2-벤조피란-3,4′-피페리딘]; 1′-[4-(1-p-톨루엔술폰일-3-인돌일)-1-부틸]스피로[이소벤조푸란-1(3H), 4′피페리딘]; 1′-[4-[5-플루오로-1-(4-플루오로페닐)-3-인돌일]-1-부틸] 스피로[이소벤조푸란-1(3H), 4′-피페리딘]; 6-플루오로-1′-[4-[1-(4-플루오로페닐)-3-인돌일]-1-부틸]스피로[이소벤조푸란-1-(3H), 4′-피페리딘]; 1′-[4-[1-(4-메틸페닐)-3-인돌일]-1-부틸] 스피로[1H-2-벤조피란-4(3H), 4′-피페리딘]; 1-(4-플루오로페닐)-3-[4-(4-(4-플루오로페닐)-1-피페리딜)-1-부틸]인돌; 1′-[4-1-(2-티아졸일)-3-인돌일]-1-부틸] 스피로[이소벤조푸란-1(3H), 4′-피페리딘]; 1′-[3-(5-플루오로벤조푸란-3-일)-1-프로필]스피로[이소벤조푸란-1(3H), 4′-피페리딘]; 1′-[3-(5-플루오로벤조푸란-3-일-부틸]스피로[이소벤조푸란-1(3H), 4′-피페리딘]; 1′-[4-[1-(4-플루오로페닐)-5-트리플루오로메틸인다졸-3-일]-1-부틸]스피로[이소벤조푸란-1(3H), 4′-피페리딘]; 4-플루오로페닐-3-[4-(4-(4-플루오로페닐)-1-피페리딘일)-1-부틸]-5-트리플루오로메틸-인다졸; 1′-(4-(1,2-벤즈이속사졸-3-일)-1-부틸)스피로[이소벤조푸란-1(3H), 4′-피페리딘]; 및 1′-[3-(벤조[b]티오펜-3-일티오)-1-프로필]스피로[이소벤조푸란-1(3H), 4′-피페리딘]; 로 구성된 군으로 부터 선택되는 것인 것을 특징으로 하는 피페리딘 화합물의 이용.
  7. 제1항에 규정된 일반식 I화합물이 R1이 상기 b)에서 정의한 바와같은 식 II의 기이고, Z1, Z2및 Z3가 상기 ii)에서 정의한 바와같고, X는 NH, Y는 CH이며, Y로 부터의 점선이 하나의 결합인 경우, -Q1-U-Q2는 탄소수가 5보다 적은 알킬이 아닐수 있고; R1이 Z3은 O, Z1은 CH2, Z2는 (CH2)n(여기서 n=0), X는 O, Y는 N인 앞서정의한 식 II의 기이고, Y로 부터의 점선은 하나의 결합을 나타내고, -Q1-U-Q2가 -(CH2)3인 경우, Rc는 플루오로가 아닐 수 있고; Z3은 O, Z2및 Z1은 모두 CH2이고 D-B-A-R은 선택적으로 치환된 펜에틸인 경우, R6은 메톡시가 아닐수 있으며; 그리고 Z1이 O, Z2및 Z3가 모두 CH2인 경우, D-B-A-R은 펜에틸, 또는 선택적으로 히드록시 치환된 헥실 또는 헵틸이 아닐 수 있는 것을 특징으로 하는 피페리딘 화합물 또는 이것의 산부가염 또는 프로-드러그.
  8. 제7항에 있어서, Z1및 Z2가 함께 결합된 경우 Z1, Z2및 Z3중 적어도 하나는 O 또는 S인 것을 특징으로 하는 피페리딘 화합물 또는 이것의 산부가염 또는 프로-드러그.
  9. 제8항에 있어서, 일반식 I의 화합물이 Z3은 n이 0인 (CH2)n이고, Z2는 “O” 또는 “S”이며 Z1은 CH2이거나 Z1및 Z2가 함께 CH2-O-CH2인 화합물인 것을 특징으로 하는 피페리딘 화합물 또는 이것의 산부가염 또는 프로-드러그.
  10. 제8항에 있어서, 일반식 I의 화합물이 Z1은 CH2, Z2는 O이고 Z3은 CH2인 것; Z3은 O이고 Z1-Z2는 CH=CH인것; 또는 Z1은 O, Z3은 O이며 Z2는 n=0인 (CH2)n인 화합물인 것을 특징으로 하는 피페리딘 화합물 또는 이것의 산부가염 또는 프로-드러그.
  11. 제7항에 있어서, 일반식 I의 화합물이 Z1및 Z2가 함께 결합되어 있지 않고 Z3은 n이 0인 (CH2)n인 화합물인 것을 특징으로 하는 피페리딘 화합물 또는 이것의 산부가염 또는 프로-드러그.
  12. 제7항에 있어서, 상기 화합물이 1′-(3-아다만틸옥시-1-프로필) 스피로[3H-2-벤조피란-3,4′-피페리딘); 1′-[4-(1-벤질-3-인돌일)-1-부틸]-스피로[이소벤조푸란-1(3H), 4′-피페리딘]; 1′-(3-(3-페닐이미다졸리딘-2-온-1-일)-1-프로필) 스피로[이소벤조푸란-1(3H), 4′-피페리딘]; 1′-[4-[-1-(4-플루오로페닐)-3-인돌일)-1-부틸]-스피로[3H-2-벤조피란-3,4′-피페리딘]; 1′-[4-[1-P-톨루엔술폰일-3-인돌일)-1-부틸]-스피로[이소벤조푸란-1(3H), 4′-피페리딘]; 1,4-디히드로-1′-[4-[1-(4-플루오로페닐)-3-인돌일]-1-부틸] 스피로[이소벤조푸란-1(3H), 4′-피페리딘]; 1′-[4-(1-p-톨루엔술폰일-3-인돌일)-1-부틸) 스피로[이소벤조푸란-1(3H), 4′-피페리딘]; 1′-[4-[5-플루오로-1-(4-플루오로페닐)-3-인돌일]-1-부틸] 스피로[이소벤조푸란-1(3H), 4′-피페리딘]; 6-플루오로-1′-[4-[1-(4-플루오로페닐)-3-인돌일]-1-부틸] 스피로[이소벤조푸란-1(3H), 4′-피페리딘]; 1′-[4-[1-(4-메틸페닐)-3-인돌일]-1-부틸] 스피로[1H-2-벤조푸란-1(3H), 4′-피페리딘]; 1-(4-플루오로페닐)-3-[4-(4-(4-플루오로페닐)-1-피페리딜)-1-부틸]인돌; 1′-[4-(1-(2-티아졸일)-3-인돌일]-1-부틸] 스피로[이소벤조푸란-1(3H), 4′-피페리딘]; 1′-[3-(5-플루오로벤조푸란-3-일)-1-프로필] 스피로[이소벤조푸란-1(3H), 4′-피페리딘]; 1′-[4-(5-플루오로벤조푸란-3-일)-1-부틸] 스피로[이소벤조푸란-1(3H), 4′-피페리딘]; 1′-[4-[1-(4-플루오로페닐)-5-트리풀루오로메틸인다졸-3-일]-1-부틸] 스피로[이소벤조푸란-1(3H), 4′-피페리딘]; 4-플루오로페닐-3-[4-(4-(4-플루오로페닐)-1-피페리딘일)-1-부틸]-5-트리플루오로메틸-인다졸; 1′-(4-(1,2-벤즈이속사졸-3-일)-1-부틸)스피로[이소벤조푸란-1(3H), 4′-피페리딘]; 및 1′-[3-(벤조[b] 티오펜-3-일티오)-1-프로필] 스피로[이소벤조푸란-1(3H), 4′-피페리딘]; 로 구성된 군으로 부터 선택되는 것인 것을 특징으로 하는 피페리딘 화합물 또는 이것의 산분가염 또는 프로-드러그.
  13. 하나 이상의 약제학적으로 허용되는 담체 또는 희석제와 함께 제6항에 따른 적어도 하나의 피페리딘 화합물 또는 이것의 약제학적으로 허용되는 산부가염 또는 프로-드러그로 구성된 것을 특징으로 하는 약제학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930703860A 1991-06-13 1992-06-12 불안 해소 효과를 갖는 피페리딘 유도체 KR100212231B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DK113191A DK113191D0 (da) 1991-06-13 1991-06-13 Spirocycliske forbindelser
DK112991A DK112991D0 (da) 1991-06-13 1991-06-13 Carbocycliske eller heterocycliske forbindelser
DK1131/91 1991-06-13
DK1129/91 1991-06-13
DK15792A DK15792D0 (da) 1992-02-10 1992-02-10 Spirocyclic compounds
DK157/92 1992-02-10
PCT/DK1992/000183 WO1992022554A1 (en) 1991-06-13 1992-06-12 Piperidine derivates having anxiolytic effect

Publications (2)

Publication Number Publication Date
KR940701397A true KR940701397A (ko) 1994-05-28
KR100212231B1 KR100212231B1 (ko) 1999-08-02

Family

ID=27220471

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930703860A KR100212231B1 (ko) 1991-06-13 1992-06-12 불안 해소 효과를 갖는 피페리딘 유도체

Country Status (22)

Country Link
US (4) US5665725A (ko)
EP (4) EP0593511B1 (ko)
JP (3) JP2834577B2 (ko)
KR (1) KR100212231B1 (ko)
AT (2) ATE239022T1 (ko)
AU (1) AU664557B2 (ko)
CA (1) CA2111204C (ko)
CZ (1) CZ289479B6 (ko)
DE (2) DE69226867T2 (ko)
DK (1) DK0593511T3 (ko)
ES (1) ES2123557T3 (ko)
FI (2) FI108137B (ko)
HK (1) HK1009272A1 (ko)
HU (1) HU210869A9 (ko)
IE (3) IE990568A1 (ko)
IL (1) IL102155A0 (ko)
NO (4) NO934494D0 (ko)
NZ (1) NZ243065A (ko)
RU (1) RU2142952C1 (ko)
SG (1) SG48237A1 (ko)
SK (3) SK281747B6 (ko)
WO (1) WO1992022554A1 (ko)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW263504B (ko) * 1991-10-03 1995-11-21 Pfizer
GB9305641D0 (en) * 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
JPH08511522A (ja) * 1993-06-07 1996-12-03 メルク エンド カンパニー インコーポレーテッド ニューロキニンアンタゴニストとしてのスピロ置換アザ環
US5607936A (en) * 1994-09-30 1997-03-04 Merck & Co., Inc. Substituted aryl piperazines as neurokinin antagonists
GB9510459D0 (en) 1995-05-24 1995-07-19 Zeneca Ltd Bicyclic amines
US5654316A (en) * 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
DE69637097T2 (de) * 1995-10-13 2007-09-20 Neurosearch A/S 8-Azabicyclo(3.2.1)Oct-2-en-Derivate, deren Herstellung und Anwendung
CA2251851A1 (en) * 1996-05-13 1997-11-20 Roger Salmon Bicyclic amines as insecticides
WO1998008816A1 (fr) * 1996-08-26 1998-03-05 Meiji Seika Kaisha, Ltd. Derives d'indoxyle et psychotropes
GB9623944D0 (en) * 1996-11-15 1997-01-08 Zeneca Ltd Bicyclic amine derivatives
GB9624114D0 (en) * 1996-11-20 1997-01-08 Zeneca Ltd Pesticidal bicyclic amine derivatives
GB9624611D0 (en) * 1996-11-26 1997-01-15 Zeneca Ltd Bicyclic amine compounds
TR199901704T2 (xx) 1996-11-26 1999-12-21 Zeneca Limited 8-Azabisiklo$3.2.1]oktan-, 8-azabisiklo$3.2.1]okt-6-en-,9-azabisiklo$3.3.1] nonan-,9-aza-3-oksabisiklo$3.3.1]nonan-ve 9-aza-3-tiabisiklo$3.3.1]nonan t�revleri, bunlar�n haz�rlanmas� ve insektisidler olarak kullan�mlar�.
GB9704948D0 (en) * 1997-03-11 1997-04-30 Knoll Ag Therapeutic agents
US6376505B1 (en) 1997-05-29 2002-04-23 Eli Lilly And Company 5-HT1A and 5-HT1Dαdalpha antagonists
JP2002500668A (ja) * 1997-05-29 2002-01-08 イーライ・リリー・アンド・カンパニー ５−ＨＴ▲下１Ａ▼および５−ＨＴ▲下１Ｄα▼アンタゴニスト
DE19725664A1 (de) 1997-06-18 1998-12-24 Merck Patent Gmbh 3-Benzylpiperidine
JP3526581B2 (ja) 1997-07-08 2004-05-17 ハー・ルンドベック・アクティーゼルスカブ シタロプラムの製造方法
UA64769C2 (uk) * 1997-11-07 2004-03-15 Х. Луннбек А/С Гідрогалогеніди 1'-[4-[1-(4-фторофеніл)-1н-індол-3-іл]-1-бутил]-спіро[ізобензофуран-1(3н),4'-піперидину], фармацевтична композиція та спосіб лікування
CZ292911B6 (cs) 1997-11-11 2004-01-14 H. Lundbeck A/S Způsob výroby citalopramu
US6013652A (en) * 1997-12-04 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin antagonists
US6166209A (en) * 1997-12-11 2000-12-26 Hoffmann-La Roche Inc. Piperidine derivatives
PL342989A1 (en) 1998-04-07 2001-07-16 Lundbeck & Co As H Treatment of panic attacks
ES2182509T3 (es) * 1998-04-08 2003-03-01 Wyeth Corp Derivados de n-ariloxietilamina para el tratamiento de la depresion.
SK3502001A3 (en) 1998-09-15 2001-12-03 Lundbeck & Co As H Use of 1'-[4-[1-(4-fluorophenyl)-1h-indole-3-yl]-1-butyl]- spiro[isobenzofuran-1(3h),4'-piperidine] for the treatment of depression
US6506378B1 (en) 1998-12-16 2003-01-14 Arch Development Corporation Vesicular monoamine transporter gene therapy in Parkinson's disease
TWI243173B (en) 1999-11-17 2005-11-11 Akzo Nobel Nv Spiro[2H-1-benzopyran-2,4'-piperidine] derivatives
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7211594B2 (en) 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
JP4745491B2 (ja) * 2000-10-11 2011-08-10 株式会社明治 インドール長鎖アルコール及びこれを含有する医薬
US7429599B2 (en) 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
AR035521A1 (es) * 2000-12-22 2004-06-02 Lundbeck & Co As H Derivados de 3-indolina y composicion farmaceutica que los comprende
WO2002069973A1 (en) * 2001-03-02 2002-09-12 Sepracor, Inc. Piperidine-piperazine ligand for neurotransmitter receptors
WO2002102387A1 (en) * 2001-06-18 2002-12-27 H. Lundbeck A/S Treatment of neuropathic pain
US20030078278A1 (en) * 2001-06-26 2003-04-24 Pfizer Inc. Spiropiperidine compounds as ligands for ORL-1 receptor
US6727264B1 (en) 2001-07-05 2004-04-27 Synaptic Pharmaceutical Corporation Substituted anilinic piperidines as MCH selective antagonists
DE10153346A1 (de) 2001-10-29 2004-04-22 Grünenthal GmbH Substituierte Indole
WO2003068741A1 (en) 2002-02-13 2003-08-21 Meiji Dairies Corporation Indole derivatives substituted with long-chain alcohols and medicaments containing them
CA2478338A1 (en) 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Combination therapy for treating, preventing or managing proliferative disorders and cancers
AU2003263155A1 (en) * 2002-09-20 2004-04-08 H. Lundbeck A/S Method for manufacture of dihydroisobenzofuran derivatives
AU2003284984B2 (en) * 2002-10-30 2008-10-23 Merck Sharp & Dohme Corp. Gamma-aminoamide modulators of chemokine receptor activity
CA2520220A1 (en) * 2003-03-31 2004-10-14 Pirelli & C. S.P.A. Thermoplastic material comprising a vulcanized rubber in a subdivided form
WO2004110387A2 (en) * 2003-06-12 2004-12-23 Agy Therapeutics, Inc. Sigma ligands for neuronal regeneration and functional recovery
US20060052386A1 (en) * 2003-06-12 2006-03-09 Tadeusz Wieloch Sigma ligands for neuronal regeneration and functional recovery
US7008953B2 (en) 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
WO2006023852A2 (en) * 2004-08-19 2006-03-02 Vertex Pharmaceuticals, Incorporated Modulators of muscarinic receptors
US7786141B2 (en) * 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
CA2576144C (en) 2004-08-27 2012-12-11 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
EP1634872A1 (en) * 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
EP1634873A1 (en) 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
CA2577089A1 (en) * 2004-08-27 2006-03-02 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
ES2396421T3 (es) 2004-08-27 2013-02-21 Laboratorios Del Dr. Esteve, S.A. Inhibidores del receptor sigma
KR20070086756A (ko) * 2004-11-29 2007-08-27 버텍스 파마슈티칼스 인코포레이티드 무스카린성 수용체의 조절제
WO2007028638A1 (en) 2005-09-09 2007-03-15 Euro-Celtique S.A. Fused and spirocycle compounds and the use thereof
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007063385A2 (en) * 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
CA2634456A1 (en) 2005-12-22 2007-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
CN101426499A (zh) 2006-02-22 2009-05-06 弗特克斯药品有限公司 毒蕈碱受体调节剂
NZ570497A (en) * 2006-02-22 2011-09-30 Vertex Pharma Spiro condensed 4,4'-quinilino-piperidines derivatives as modulators of muscarinic receptors
MX2008011016A (es) 2006-03-01 2008-09-08 Esteve Labor Dr Inhibidores de receptor sigma.
EP1829875A1 (en) 2006-03-01 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
EP1829866A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
EP1829867A1 (en) 2006-03-03 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Imidazole compounds having pharmaceutical activity towards the sigma receptor
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
US7858790B2 (en) 2006-06-29 2010-12-28 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US7696201B2 (en) 2006-08-15 2010-04-13 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
EP2051715A2 (en) * 2006-08-18 2009-04-29 Vertex Pharmceuticals Incorporated Modulators of muscarinic receptors
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008067661A1 (en) * 2006-12-05 2008-06-12 Ibco Srl Stretchable scrim wrapping material
AU2008205642B2 (en) 2007-01-12 2013-06-06 Msd K.K. Spirochromanon derivatives
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
CL2008000070A1 (es) * 2007-01-17 2008-07-25 Lg Life Sciences Ltd Monosal del acido maleico (3-[({1-[(2-amino-9h-purin-9-il)metil]ciclopropil}oxi)metil]-8,8-dimetil-3,7-dioxo-2,4,6-trioxa-3 lambda 5-fosfanon-1-il-pivalato; composicion farmaceutica que comprende a dicha monosal; y uso para el tratamiento del virus h
JP2010540640A (ja) * 2007-10-03 2010-12-24 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン作用性レセプターのモジュレーター
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
RU2707067C2 (ru) 2009-12-04 2019-11-22 Суновион Фармасьютикалз, Инк. Полициклические соединения и способы их применения
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
ES2586212T3 (es) * 2010-02-04 2016-10-13 Laboratorios Del Dr. Esteve, S.A. Polimorfos y solvatos de clorhidrato de 4-[2-[[5-metil-1-(2-naftalenil)-1H-pirazol-3-il]oxi]etil]morfolina
MX2012008721A (es) * 2010-02-16 2012-08-17 Pfizer (r)-4-((4-((4-(tetrahidrofuran-3-iloxi)benzo[d]isoxazol-3-iloxi)m etil) tetrahidro-2h-piran-4-ol, un agonista pacial de receptores 5-ht4.
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2395003A1 (en) 2010-05-27 2011-12-14 Laboratorios Del. Dr. Esteve, S.A. Pyrazole compounds as sigma receptor inhibitors
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
US20130333095A1 (en) * 2012-06-14 2013-12-19 Michael Dudick Cap with cap replacement section
CA2933511A1 (en) 2013-12-17 2015-06-25 Laboratorios Del Dr. Esteve, S.A. Serotonin-norepinephrine reuptake inhibitors (snris) and sigma receptor ligands combinations
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
PT3413870T (pt) 2016-02-11 2021-09-10 Sigmathera Sas Igmesina para utilização no tratamento de doença de alzheimer
RU2691454C2 (ru) * 2016-03-30 2019-06-14 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Использование 3,4,5-триметокси-N'(2,2,6,6-тетраметил-пиперидин-4-илиден)бензогидразида гидрохлорида в качестве анксиолитического средства
EP3490607A4 (en) 2016-07-29 2020-04-08 Sunovion Pharmaceuticals Inc. COMPOUNDS AND COMPOSITIONS, AND USES THEREOF
MA45857A (fr) 2016-07-29 2021-05-19 Sunovion Pharmaceuticals Inc Composés et compositions, et utilisations associées
CN116808023A (zh) 2017-02-16 2023-09-29 桑诺维恩药品公司 治疗精神分裂症的方法
JP7191085B2 (ja) 2017-08-02 2022-12-16 サノビオン ファーマシューティカルズ インク イソクロマン化合物およびその使用
MX2020008537A (es) 2018-02-16 2021-01-08 Sunovion Pharmaceuticals Inc Sales, formas cristalinas y metodos de produccion de las mismas.
EP3938045A1 (en) 2019-03-14 2022-01-19 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
IL297248A (en) 2020-04-14 2022-12-01 Sunovion Pharmaceuticals Inc (s)-(5,4-dihydro-7h-thiano[3,2-c]pyran-7-yl)-n-methylmethanamine for the treatment of neurological and psychiatric disorders
WO2021236879A1 (en) 2020-05-20 2021-11-25 The Board Of Trustees Of The University Of Illinois Method for treating lysosomal storage diseases with histatin peptides

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2891066A (en) * 1957-08-14 1959-06-16 Parke Davis & Co 4,o-substituted phenyl 1 alkanol piperidines and esters thereof
GB944443A (ko) * 1959-09-25 1900-01-01
FR1335831A (fr) * 1962-10-09 1963-08-23 Res Lab Dr C Janssen Nv Procédé de préparation de nu-(3, 3-diphényl-3-alcanoyl)-propylspiro
US3408356A (en) * 1965-08-31 1968-10-29 Squibb & Sons Inc Long chain esters of 4'-fluoro-4-[4-hydroxy-4-(alpha, alpha, alpha-trifluorotolyl)piperi-dino]butyrophenone and the like
GB1154976A (en) * 1967-02-21 1969-06-11 Pfizer Ltd N-Phenyl Indoline Derivatives
US3476760A (en) * 1967-03-06 1969-11-04 Smithkline Corp Substituted piperidinoalkylthianaphthenes and benzofurans
US3654287A (en) * 1970-08-26 1972-04-04 Mead Johnson & Co Spiroindanylpiperidines
US3686213A (en) * 1970-08-28 1972-08-22 American Cyanamid Co Substituted aminoethyl indoles
US3686186A (en) * 1970-10-05 1972-08-22 William J Houlihan Substituted isochroman or phthalan piperidenes
US3745165A (en) * 1970-10-05 1973-07-10 Sandoz Ag Substituted isochroman or phthalan piperidenes
US4021451A (en) * 1972-05-16 1977-05-03 American Home Products Corporation Process for preparing polycyclic heterocycles having a pyran ring
DE2322470A1 (de) * 1973-05-04 1974-11-21 Boehringer Sohn Ingelheim Neue indolyl-piperidino-(bzw. 1,2,5,6tetrahydro-pyridyl-)butyrophenone und verfahren zu ihrer herstellung
GB1469108A (en) * 1973-06-25 1977-03-30 Kefalas As Thiaxanthene derivative
US4038395A (en) * 1973-06-25 1977-07-26 Kefalas A/S Compositions of and method of treating with the alpha-isomer of 2-chloro-9-[3'-(N'-2-hydroxyethylpiperazino-N)-propylidene]-thiaxanthene, carboxylic acid esters thereof and acid addition salts of these compounds
US3962259A (en) * 1973-12-12 1976-06-08 American Hoechst Corporation 1,3-Dihydrospiro[isobenzofuran]s and derivatives thereof
FR2258843B1 (ko) * 1974-01-30 1977-09-09 Roussel Uclaf
DE2433769A1 (de) 1974-07-13 1976-01-22 Seelemann Baumann Gmbh Vorreisserwalze fuer open-end spinnmaschinen
US3936464A (en) * 1974-10-25 1976-02-03 American Cyanamid Company 1-Acyl-3-[2-(4-phenyl-1-piperidinyl)ethyl]indolines
IL48508A (en) * 1974-12-09 1979-10-31 Roussel Uclaf Pharmaceutical compositions comprising piperidylindole derivatives
FR2354766A1 (fr) * 1976-06-17 1978-01-13 Labaz Derives n-aminoalkyles d'indole et procedes pour les preparer
FR2362628A1 (fr) * 1976-08-26 1978-03-24 Roussel Uclaf Nouveaux derives du piperidyl-indole et leurs sels, procede de preparation et application a titre de medicaments
FR2421900A1 (fr) * 1977-03-17 1979-11-02 Sauba Lab Piperazino-3-indoles, leur procede de preparation et leurs applications therapeutiques
FR2391211A2 (fr) * 1977-05-18 1978-12-15 Roussel Uclaf Nouveaux derives de 2,3-dihydroa(4-(3-indolyl) 1-piperidinyl) methyl 1,4-benzodioxin-2-methanol, un procede de preparation, et leur application comme medicaments
GB1587961A (en) 1977-10-11 1981-04-15 Eadie Bros & Co Ltd Card-clothing
EG13536A (en) * 1977-12-02 1981-12-31 Hoechst Ag Substituted 1,3-dihydrospiro(benzo(c)thiophene)s
US4166119A (en) * 1978-04-14 1979-08-28 American Hoechst Corporation Analgesic and tranquilizing spiro[dihydrobenzofuran]piperidines and pyrrolidines
DE2827874A1 (de) * 1978-06-24 1980-02-07 Merck Patent Gmbh Indolalkylamine und verfahren zu ihrer herstellung
DE2961867D1 (en) * 1978-06-24 1982-03-04 Merck Patent Gmbh Indolylalkyl amines, pharmaceutical preparations containing them and process for their manufacture
US4208417A (en) * 1978-06-29 1980-06-17 Pharmindustrie Indole derivatives and their use as anxiolytics
JPS55139381A (en) * 1979-04-13 1980-10-31 Dai Ichi Seiyaku Co Ltd Spiroisochroman
JPS55143980A (en) * 1979-04-27 1980-11-10 Dai Ichi Seiyaku Co Ltd Anti-allergic preparation
SE8004129L (sv) * 1979-07-13 1981-01-14 Roussel Uclaf Nya tetrahydropyridin-4-yl-indolderivat samt salter derav, framstellning och anvendning derav sasom lekemedel samt kompositioner innehallande dessa foreningar
NZ196284A (en) * 1980-02-29 1983-12-16 Kefalas As 1-piperazino-3-phenylindane derivatives:pharmaceutical compositions
US4358456A (en) * 1980-05-03 1982-11-09 John Wyeth & Brother Limited Antipsychotic piperidinomethyl-indole derivatives
US4302589A (en) * 1980-05-08 1981-11-24 American Cyanamid Company Cis-mono and disubstituted-2-methyl-3-[(piperazinyl) and (piperidino)ethyl]indolines, intermediates for their preparation and methods of preparation
DE3267658D1 (en) * 1981-04-27 1986-01-09 Hoechst Roussel Pharma 1-(3-(6-fluoro-1,2-benzisoxasol-3-yl)propyl)-4-hydroxy-4-phenylpiperidines, a process for their preparation and their use as medicaments
EP0077607A1 (en) * 1981-09-17 1983-04-27 Beecham Group Plc N-substituted 3-aryl piperidines and derivatives thereof
US4524207A (en) * 1981-10-20 1985-06-18 Hoechst-Roussel Pharmaceuticals Inc. Process for preparing substituted 1,3-dihydrospiro[benzo(c)thiophene]s
US4591586A (en) * 1982-04-09 1986-05-27 Hoechst-Roussel Pharmaceuticals 6-fluoro-3-[3-(1-heterocyclo)propyl]-1,2-benzisoxazoles for treatment of pain, hypertension and psychoses
US4420485A (en) * 1982-09-29 1983-12-13 Hoechst-Roussel Pharmaceuticals Inc. 1'-[3-(1,2-Benzisoxazol-3-yl) proply]spiro[benzofuran-2(3H),3' or 4'-piperidines or 3'-pyrrolidines]
FR2533924A1 (fr) * 1982-10-05 1984-04-06 Roussel Uclaf Nouveaux derives du 4-(1h-indol-3-yl)a-methyl piperidine-1-ethanol, leurs sels, le procede de preparation, l'application a titre de medicaments et les compositions les renfermant
IE55972B1 (en) * 1982-10-07 1991-03-13 Kefalas As Phenylindene derivatives,acid addition salts thereof,and methods of preparation
US4670447A (en) * 1983-08-22 1987-06-02 Hoechst-Roussel Pharmaceuticals Inc. Antipsychotic 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles
HU198036B (en) * 1983-08-22 1989-07-28 Hoechst Roussel Pharma Process for production of derivatives of 3-piperidil-/1h/-indasole and medical preparatives containing them
US4853470A (en) * 1983-08-22 1989-08-01 Hoechst-Roussel Pharmaceuticals, Inc. 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles
US4452802A (en) * 1983-08-25 1984-06-05 Hoechst-Roussel Pharmaceuticals Incorporated Antihypertensive spiro[benzofuran-azalkanes]
GB8422924D0 (en) * 1984-09-11 1984-10-17 Wyeth John & Brother Ltd Prevention of hypertension
GB8427125D0 (en) * 1984-10-26 1984-12-05 Lundbeck & Co As H Organic compounds
EP0367300B1 (en) * 1985-02-28 1992-07-22 Symbol Technologies, Inc. Portable laser diode scanning head
DE3509333A1 (de) * 1985-03-15 1986-09-18 Hoechst Ag, 6230 Frankfurt Substituierte benzimidazolderivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zubereitungen und ihre verwendung als magensaeuresekretionshemmer
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
DE3521761A1 (de) * 1985-06-19 1987-01-02 Bayer Ag Neue 1,4-dihydropyridine, verfahren zur herstellung und ihre verwendung in arzneimitteln
US4742057A (en) * 1985-12-05 1988-05-03 Fujisawa Pharmaceutical Co., Ltd. Antiallergic thiazole compounds
DE3630903A1 (de) * 1986-09-11 1988-03-24 Thomae Gmbh Dr K Neue tetrahydronaphthalin- und indanderivate, verfahren zu deren herstellung sowie diese enthaltende arzneimittel
GB8628644D0 (en) * 1986-12-01 1987-01-07 Lunbeck A S H Intermediates
GB8704572D0 (en) * 1987-02-26 1987-04-01 Lundbeck & Co As H Organic compounds
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
EP0302423A3 (en) * 1987-08-07 1991-01-09 Hoechst-Roussel Pharmaceuticals Incorporated 1-phenyl-3-(1-piperazinyl)-1h-indazoles, a process and intermediates for their preparation, and the use thereof as medicaments
KR0131327B1 (en) * 1987-08-13 1998-04-17 Glaxo Group Ltd Indole derivatives
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
FR2640266B2 (fr) * 1988-07-12 1992-07-10 Synthelabo Derives de (hydroxy-1 piperidinyl-2 alkyl) indolones-2, quinoleinones-2, benzo(b)azepinones-2 et benzimidazolones-2, leur preparation et leur application en therapeutique
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
HU207310B (en) * 1988-12-02 1993-03-29 Pfizer Process for producing aryl-piperidine derivatives
GB8830312D0 (en) * 1988-12-28 1989-02-22 Lundbeck & Co As H Heterocyclic compounds
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
WO1990014067A2 (en) * 1989-05-02 1990-11-29 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Methods for treating anxiety with sigma receptor ligands
SE8901889D0 (sv) * 1989-05-26 1989-05-26 Astra Ab Novel 8-substituted-2-aminotetralines
GB8917069D0 (en) * 1989-07-26 1989-09-13 Merck Sharp & Dohme Therapeutic agents
US5109002A (en) * 1989-09-08 1992-04-28 Du Pont Merck Pharmaceutical Company Antipsychotic 1-cycloalkylpiperidines
AU629073B2 (en) 1989-12-07 1992-09-24 De Beers Industrial Diamond Division (Proprietary) Limited Material separation
IL96507A0 (en) * 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
FR2662696A2 (fr) * 1989-12-13 1991-12-06 Rhone Poulenc Sante Antagonistes de la serotonine, leur preparation et medicaments les contenant.
CA2071897A1 (en) * 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof
EP0445974A3 (en) * 1990-03-05 1992-04-29 Merck Sharp & Dohme Ltd. Spirocyclic antipsychotic agents
DK152090D0 (da) * 1990-06-22 1990-06-22 Lundbaek A S H Piperidylsubstituerede indolderivater
DK158590D0 (da) * 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater
DK181190D0 (da) * 1990-07-30 1990-07-30 Lundbeck & Co As H 3-aryl-indol- eller 3-aryl-indazolderivater
DK238190D0 (da) * 1990-10-03 1990-10-03 Lundbeck & Co As H Depotderivater
DK286990D0 (da) * 1990-12-04 1990-12-04 Lundbeck & Co As H Indanderivater
GB9501222D0 (en) 1995-01-21 1995-03-15 English Card Clothing The Comp Card-clothing wire

Also Published As

Publication number Publication date
SK281747B6 (sk) 2001-07-10
EP0518805A1 (en) 1992-12-16
JPH10316659A (ja) 1998-12-02
HK1009272A1 (en) 1999-05-28
NO994487D0 (no) 1999-09-16
EP0593511B1 (en) 1998-09-02
HU210869A9 (en) 1995-08-28
FI935558A (fi) 1993-12-10
WO1992022554A1 (en) 1992-12-23
IE990567A1 (en) 2001-03-21
NO310275B1 (no) 2001-06-18
DE69226867T2 (de) 1999-05-12
DE69226867D1 (de) 1998-10-08
US6031099A (en) 2000-02-29
RU2142952C1 (ru) 1999-12-20
FI19992135A (fi) 1999-10-04
FI935558A0 (fi) 1993-12-10
DE69233038D1 (de) 2003-06-05
IL102155A0 (en) 1993-01-14
US5665725A (en) 1997-09-09
EP0859004B1 (en) 2003-05-02
CZ272693A3 (en) 1994-04-13
DK0593511T3 (da) 1999-05-31
ES2123557T3 (es) 1999-01-16
EP0593511A1 (en) 1994-04-27
NO994488L (no) 1994-02-11
SK140993A3 (en) 1994-11-09
SK281748B6 (sk) 2001-07-10
ATE170523T1 (de) 1998-09-15
DE69233038T2 (de) 2003-12-11
CA2111204A1 (en) 1992-12-23
US6207677B1 (en) 2001-03-27
CA2111204C (en) 2001-02-27
US5807871A (en) 1998-09-15
JPH111475A (ja) 1999-01-06
NO934494L (no) 1994-02-11
SK280899B6 (sk) 2000-09-12
JP2834577B2 (ja) 1998-12-09
CZ289479B6 (cs) 2002-01-16
IE990568A1 (en) 2001-03-21
AU664557B2 (en) 1995-11-23
NZ243065A (en) 1995-07-26
IE921882A1 (en) 1992-12-16
NO306497B1 (no) 1999-11-15
EP0859004A1 (en) 1998-08-19
ATE239022T1 (de) 2003-05-15
SG48237A1 (en) 1998-04-17
FI112480B (fi) 2003-12-15
EP0853085A1 (en) 1998-07-15
JP3203230B2 (ja) 2001-08-27
NO994488D0 (no) 1999-09-16
NO994487L (no) 1994-02-11
KR100212231B1 (ko) 1999-08-02
NO934494D0 (no) 1993-12-09
FI108137B (fi) 2001-11-30
JPH06508360A (ja) 1994-09-22
AU1984892A (en) 1993-01-12

Similar Documents

Publication Publication Date Title
KR940701397A (ko) 불안해소 효과를 갖는 피페리딘 유도체
WO2004009548A1 (en) 1-heterocyclylalkyl-3-sulfonylindole or -indazole derivatives as 5-hydroxytryptamine-6 ligands
US20040092526A1 (en) Heterocyclylindazole and -azaindazole compounds as 5-hydroxytryptamine-6 ligands
WO2008046083A2 (en) Use of oxindole compounds as therapeutic agents
KR920002586A (ko) 신규 인돌 유도체
RU93058600A (ru) Производные пиперидина, обладающие анксиолитическим действием, фармацевтическая композиция на их основе
KR950701910A (ko) 이합 피페리딘, 테트라히드로피리딘 및 피페라진 유도체(Dimeric Piperidine, Tetrahydropyridine and Piperazine Derivatives)
HUP0103256A2 (hu) Tio-benzimidazol-származékok, és a vegyületeket tartalmazó gyógyászati készítmények
US20120302620A1 (en) Novel pyrone-indole derivatives and process for their preparation
DE68908040D1 (de) 3-(4-piperidin)-5-(2-sulphonylaminoethyl)-indol-derivate.
JP6584960B2 (ja) フェノキシピペリジンコア構造を含むｈ３アンタゴニスト
AU663699B2 (en) Treatment of cognitive disorders
MX2007006757A (es) Tetrahidropiridin-4-il-indoles con una combinacion de afinidad para receptores de dopamina-d2 y sitios de reabsorcion de serotonina.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20090423

Year of fee payment: 11

LAPS Lapse due to unpaid annual fee